following an abbreviated submission:
brolucizumab (Beovu®) is accepted for restricted use within NHSScotland.
Indication under review: in adults for the treatment of visual impairment due to diabetic macular oedema.
SMC restriction: treatment of visual impairment due to diabetic macular oedema in adults with best corrected visual acuity 75 Early Treatment Diabetic Retinopathy Study letters or less at baseline.
Brolucizumab offers an additional treatment choice in the class of vascular endothelial growth factor inhibitors in this indication.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice732KB (PDF)
Medicine details
- Medicine name:
- brolucizumab (Beovu)
- SMC ID:
- SMC2508
- Indication:
in adults for the treatment of visual impairment due to diabetic macular oedema.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 10 October 2022